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 Summary
	 Background:  Phenylketonuria	(PKU)	is	the	most	common	inborn	error	of	metabolism	in	man.	Brain	phenylalanine	
kinetics	 can	 determine	 neurological	 treatment	 outcome	 in	 phenylketonuria.	 The	 aim	 of	 our	
study	was	 to	 test	 a	 simplified	magnetic	 resonance	 spectroscopy	method	 for	 assessment	 of	 brain	
phenylalanine	dynamics	in	PKU	patients.
 Material/Methods:  Brain	phenylalanine	concentration	(measured	by	means	of	magnetic	resonance	spectroscopy)	and	
blood	phenylalanine	concentrations	changes	occurring	within	24	hours	after	oral	phenylalanine	
loading	were	analyzed	in	5	PKU	patients.
	Results/Conclusions:  The	brain/blood	phenylalanine	ratio	in	3	persons	with	normal	intelligence	was	lower	than	in	2	with	
borderline	 intelligence	 or	mild	mental	 retardation.	 In	 our	 opinion	 the	proposed	method	 could	be	
useful	for	assessment	of	brain	phenylalanine	dynamics	in	PKU	patients.
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Background
Phenylketonuria	 (PKU)	 is	 the	 most	 common	 disorder	 of	
amino	acid	metabolism	in	man.	Treatment	consists	in	life-
long	restriction	of	dietary	phenylalanine	intake	to	decrease	
its	 blood	 concentration	 as	 uncontrolled	 hyperphenylala-
ninemia	could	be	 toxic	 for	 the	brain.	The	neuropathologic	
changes	in	the	brain	include	hypomyelination	diffuse	gliosis	
and	 in	 some	cases	progressive	white	matter	degeneration.	
Usually	untreated	patients	are	severely	mentally	retarded.	
Interestingly,	some	persons	with	PKU	who	were	never	tre-
ated	do	not	show	neurological	impairment.	Several	authors	
pointed	 that	 individual	 brain	 phenylalanine	 kinetics	 can	
determine	 neurological	 treatment	 outcome	 in	 phenylke-
tonuria	 [1,	 2]	 and	 low	brain	 phenylalanine	 concentration	
despite	hyperphenylalaninemia	 is	 probably	 crucial	 for	 the	
favorable	 outcome	 in	 such	 exceptional	 individuals.	 Thus,	
measurement	of	brain	phenylalanine	concentration	in	PKU	
–	 patients	 could	 be	 useful.	 The	 method	 of	 noninvasive	
assessment	 of	 brain	 phenylalanine	 by	means	 of	magnetic	
resonance	 spectroscopy	 (MRS)	was	described	 earlier.	This	
technique	 requires,	 however,	 sophisticated	 determination	
of	a	“normal	range”	of	the	brain	spectrum	in	a	homogenous	
control	 group	of	healthy	persons	and,	 although	 reliable	 in	
adults,	 it	 is	 of	 limited	use	 in	 children	because	 of	 possible	
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age-related	 differences	 between	 brains	 of	 patients.	 We	
therefore	 intended	 to	 test	 a	 simplified	 age-independent	
method	 for	 analysis	 of	 brain	 phenylalanine	 dynamics	 in	
PKU	–	patients.
Material and Methods
Oral	 phenylalanine	 loading	 (100	mg/kg)	 with	 subsequent	
analysis	 of	plasma	phenylalanine	 concentration	 (colorime-
try)	 and	parallel	 brain	MRS	after	 12	hours	 (first	 day)	 and	
36	 hours	 (second	 day)	was	 performed	 in	 5	 early	 treated	
PKU	–	 teenagers.	MRS	was	 conducted	 on	 a	 1.5	T	 scanner	
(Magnetom	Vision	 Plus,	 Siemens)	with	 use	 of	 the	 PRESS	
(point	 resolved	 spectroscopy)	 technique,	 signal	 acquisi-
tion	from	a	volume	of	18	cm3	of	brain	white	matter,	rela-
xation	 time/echo	 time	 1500/30	ms	 and	 512	 acquisitions.	
Phenylalanine	 signal	was	 identified	 at	 7.37	ppm	and	 cre-
atine	 signal	which	 served	 as	 an	 internal	 standard	 at	 3.03	
ppm.	The	molar	change	 in	brain	phenylalanine	concentra-
tion	 (∆	 PheBrain)	was	 calculated	 from	 equation:	∆	 PheBrain	
=	 6.4	mmol/kg	 x	 [Phe1st	 day	peak	 area	 /Creatine1st	 day	 peak	
area	–	Phe2nd	day	peak	area	/Creatine2nd	day	peak	area]	x	3/5,	
as	the	phenylalanine	resonance	is	due	to	5	protons	and	the	
creatine	to	3	and	with	assumption	of	typical	white	matter	
creatine	concentration	of	6.4	mmol/kg	of	wet	weight	[3].	
Results
∆	 PheBrain	 /	 ∆	 PheBlood	 ratio	 describing	 the	 dynamics	 of	
brain	 phenylalanine	 concentration	 change	 during	 parallel	
blood	 phenylalanine	 change	 varied	 from	 0.22	 to	 0.52.	
Interestingly	 in	3	persons	with	normal	 intelligence	 it	was	
lower	 (0.22-0.25)	 than	 in	2	with	borderline	 intelligence	or	
mild	mental	 retardation	 (0.37	 and	 0.52	 respectively).	Our	
results	 seem	to	be	 in	agreement	with	 the	 results	obtained	
by	 others	 [1,	 2]	 and	 in	 our	 opinion	 the	 proposed	method	
could	be	useful	for	assessment	of	brain	phenylalanine	dyna-
mics	 in	 patients	with	PKU.	Detailed	 data	 on	 participants	
are	given	in	table	1.	Figure	1	shows	brain	spectrum	(MRS)	
of	a	PKU	–	patient	and	of	a	healthy	person.
Table 1.  Study participants and results.
Tabela 1.  Uczestnicy badania i uzyskane wyniki.
Case Age/sex IQ Brain phenylalanine decrease(mmol/kg wet weight)
Blood phenylalanine change (mmol/l) Brain/blood
phenylalanine ratio1st day 2nd day
1 16/M 134 0.046 1.69 1.51 0.25
2 15/F 90 -0.05 1.64 1.85 0.24
3 12/F 96 0.038 1.74 1.57 0.22
4 11/F 75 0.14 1.45 1.18 0.52
5 15/M 65 0.1 1.36 1.09 0.37
Figure 1.  Brain spectrum (MRS) in a PKU patient (left) and a healthy individual (right). Phe signal at 7.37 ppm.
Rycina 1.   Mózgowe spektrum (MRS) u pacjenta z PKU (po lewej) i u osoby zdrowej (po prawej). Sygnał fenyloalaniny przy 7,37 ppm.
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